BHCM
RLAY icon

Brevan Howard Capital Management’s Relay Therapeutics RLAY Stock Holding History

Brevan Howard Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-61,629
Closed -$322K – 2204
2025
Q3 		$322K Buy
+61,629
New +$235K ﹤0.01% 1533
2025
Q2 		– Sell
-46,548
Closed -$122K – 1987
2025
Q1 		$122K Buy
+46,548
New +$182K ﹤0.01% 1039
2024
Q4 		– Sell
-26,330
Closed -$186K – 1373
2024
Q3 		$186K Sell
26,330
-5,396
-17% -$40.3K ﹤0.01% 1006
2024
Q2 		$207K Buy
31,726
+6,618
+26% +$45.2K ﹤0.01% 881
2024
Q1 		$208K Buy
+25,108
New +$245K ﹤0.01% 791

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's RLAY Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Relay Therapeutics (RLAY) in Q4 2025, closing a stake of 61,629 shares — an estimated $322K sold.

Brevan Howard Capital Management first reported a position in RLAY in Q1 2024 and held it in 5 quarters. The position peaked at $322K in Q3 2025. 227 funds tracked by Wall St. Rank hold RLAY as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Relay Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 61,629 Relay Therapeutics shares in Q4 2025, an estimated $322K.
  • Brevan Howard Capital Management first reported a position in Relay Therapeutics in Q1 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's Relay Therapeutics position peaked at $322K in Q3 2025.
  • 227 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.